Head-To-Head Survey: Palmer Square Capital BDC (NYSE:PSBD) versus BR Biopharma (NASDAQ:BRBI)

BR Biopharma (NASDAQ:BRBI) and Palmer Square Capital BDC (NYSE:PSBD) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Earnings and Valuation

This table compares BR Biopharma and Palmer Square Capital BDC”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BR Biopharma	$2.23 billion	0.06	$31.36 million	$0.08	136.57
Palmer Square Capital BDC	$124.39 million	2.56	-$3.17 million	($0.99)	-10.48

BR Biopharma has higher revenue and earnings than Palmer Square Capital BDC. Palmer Square Capital BDC is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. Palmer Square Capital BDC pays an annual dividend of $1.44 per share and has a dividend yield of 13.9%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Palmer Square Capital BDC pays out -145.5% of its earnings in the form of a dividend. Palmer Square Capital BDC is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares BR Biopharma and Palmer Square Capital BDC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
Palmer Square Capital BDC	-26.73%	11.22%	4.15%

Institutional & Insider Ownership

6.5% of Palmer Square Capital BDC shares are held by institutional investors. 29.4% of BR Biopharma shares are held by insiders. Comparatively, 1.1% of Palmer Square Capital BDC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for BR Biopharma and Palmer Square Capital BDC, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
Palmer Square Capital BDC	0	5	0	0	2.00

Palmer Square Capital BDC has a consensus price target of $10.50, indicating a potential upside of 1.16%. Given Palmer Square Capital BDC’s stronger consensus rating and higher probable upside, analysts plainly believe Palmer Square Capital BDC is more favorable than BR Biopharma.

Summary

Palmer Square Capital BDC beats BR Biopharma on 8 of the 14 factors compared between the two stocks.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.

About Palmer Square Capital BDC

Palmer Square Capital BDC Inc. is an externally managed, non-diversified closed-end management investment company which primarily lends to and invests in corporate debt securities, including small to large private U.S. companies and has elected to be regulated as a business development company. Palmer Square Capital BDC Inc. is based in MISSION WOODS, Kan.